DOCS logo

Dr. Martens plcLSE:DOCS Stock Report

Market Cap UK£721.9m
Share Price
UK£0.75
My Fair Value
UK£0.90
16.8% undervalued intrinsic discount
1Y6.0%
7D-2.9%
Portfolio Value
​
View

Dr. Martens plc

LSE:DOCS Stock Report

Market Cap: UK£721.9m

Dr. Martens (DOCS) Stock Overview

Engages in the design, development, procurement, marketing, sale, and distribution of footwear. More details

DOCS fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends2/6

Rewards

Trading at 46.4% below our estimate of its fair value

Earnings are forecast to grow 47.96% per year

Risk Analysis

Dividend of 3.41% is not well covered by earnings

Large one-off items impacting financial results

Volatile share price over the past 3 months compared to the UK market

Profit margins (0.6%) are lower than last year (7.9%)


DOCS Community Fair Values

Create Narrative

See what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.

DOCS logo
Dr. Martens

High Valuations Will Suffer Rising Supply Costs And Consumer Shifts

Key Takeaways Brand faces pressure as evolving consumer values and sustainability trends undermine its traditional products, demanding costly supply chain adaptation and innovation. Intensifying digital competition and heavy reliance on legacy products erode pricing power, threaten brand relevance, and risk long-term margin and sales decline.
View narrative
UK£0.75
FV
0.4% undervalued intrinsic discount
3.22%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
15 days ago author updated this narrative
DOCS logo
Dr. Martens

Asian DTC Markets And Digital Retail Will Expand Global Reach

Key Takeaways Accelerating direct-to-consumer growth, improved pricing power, and inventory efficiency are poised to drive margin expansion and a faster-than-expected earnings rebound. Strength in Asian markets, global e-commerce expansion, and consumer preference for durable, high-quality products position the brand for sustained top-line growth and market share gains.
View narrative
UK£1.14
FV
34.5% undervalued intrinsic discount
8.61%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
1 day ago author updated this narrative
DOCS logo
Dr. Martens

Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26

Key Takeaways Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability. Stronger balance sheet with reduced debt supports future growth and financial stability through improved cash flow and inventory management.
View narrative
UK£0.90
FV
16.8% undervalued intrinsic discount
5.05%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
3 days ago author updated this narrative
View Stock Community

Dr. Martens plc Competitors

Price History & Performance

Summary of share price highs, lows and changes for Dr. Martens
Historical stock prices
Current Share PriceUK£0.75
52 Week HighUK£0.85
52 Week LowUK£0.43
Beta0.18
1 Month Change-5.62%
3 Month Change30.71%
1 Year Change5.96%
3 Year Change-71.11%
5 Year Changen/a
Change since IPO-83.40%

Recent News & Updates

Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?

Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?

Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Recent updates

Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?

Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?

Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017

Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings

Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings

Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital

Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
author-image

Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26

Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.

Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%

Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%

Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year

Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year

Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet

Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet

Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?

Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?

Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger

Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger

There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings

Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings

Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet

Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet

Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price

Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price

Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market

Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market

Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156

Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156

Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156

Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156

Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation

Oct 12
Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation

Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Sep 13
Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)

Jul 12
Returns on Capital Paint A Bright Future For Dr. Martens (LON:DOCS)

A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Jun 02
A Look At The Intrinsic Value Of Dr. Martens plc (LON:DOCS)

Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency

Feb 25
Dr. Martens (LON:DOCS) Is Investing Its Capital With Increasing Efficiency

Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?

Dec 17
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 34% Undervaluation?

The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Oct 02
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested

Shareholder Returns

DOCSGB LuxuryGB Market
7D-2.9%-0.05%1.2%
1Y6.0%-16.6%17.0%

Return vs Industry: DOCS exceeded the UK Luxury industry which returned -16.6% over the past year.

Return vs Market: DOCS underperformed the UK Market which returned 16.9% over the past year.

Price Volatility

Is DOCS's price volatile compared to industry and market?
DOCS volatility
DOCS Average Weekly Movement9.0%
Luxury Industry Average Movement4.4%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.9%
10% least volatile stocks in GB Market2.5%

Stable Share Price: DOCS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: DOCS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
19452,348Ije Nwokoriewww.drmartensplc.com

Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

Dr. Martens plc Fundamentals Summary

How do Dr. Martens's earnings and revenue compare to its market cap?
DOCS fundamental statistics
Market capUK£721.88m
Earnings (TTM)UK£4.50m
Revenue (TTM)UK£787.60m
160.4x
P/E Ratio
0.9x
P/S Ratio

Is DOCS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DOCS income statement (TTM)
RevenueUK£787.60m
Cost of RevenueUK£275.90m
Gross ProfitUK£511.70m
Other ExpensesUK£507.20m
EarningsUK£4.50m

Last Reported Earnings

Mar 30, 2025

Next Earnings Date

Nov 20, 2025

Earnings per share (EPS)0.0047
Gross Margin64.97%
Net Profit Margin0.57%
Debt/Equity Ratio67.9%

How did DOCS perform over the long term?

See historical performance and comparison

Dividends

3.4%
Current Dividend Yield
545%
Payout Ratio

Does DOCS pay a reliable dividends?

See DOCS dividend history and benchmarks
When do you need to buy DOCS by to receive an upcoming dividend?
Dr. Martens dividend dates
Ex Dividend DateAug 28 2025
Dividend Pay DateOct 08 2025
Days until Ex dividend10 days
Days until Dividend pay date51 days

Does DOCS pay a reliable dividends?

See DOCS dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/17 18:08
End of Day Share Price 2025/08/15 00:00
Earnings2025/03/30
Annual Earnings2025/03/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Dr. Martens plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard TaylorBarclays
Anne CritchlowBerenberg
David RouxBofA Global Research